ArticlePloS one2019
Leukemia multiclass assessment and classification from Microarray and RNA-seq technologies integration at gene expression level.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- AI based multiomics integration for cancer diagnosis and prognosis.Journal, genetic engineering & biotechnology · 2026Article
- Joint representation and visualization of derailed cell states with Decipher.Genome biology · 2025Article
- Margin weighted robust discriminant score for feature selection in imbalanced gene expression classification.PloS one · 2025Article
- Comparative Analysis of 3D Cephalometry Provided with Artificial Intelligence and Manual Tracing.Diagnostics (Basel, Switzerland) · 2024Article
- Improving prediction of blood cancer using leukemia microarray gene data and Chi2 features with weighted convolutional neural network.Scientific reports · 2024Article
- Article
- Diagnosis of acute myeloid leukaemia on microarray gene expression data using categorical gradient boosted trees.Heliyon · 2023Article
- Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures andBioinformatics advances · 2023Article
- A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects.Journal of medical Internet research · 2022Review
- Machine-Learning-Based Late Fusion on Multi-Omics and Multi-Scale Data for Non-Small-Cell Lung Cancer Diagnosis.Journal of personalized medicine · 2022Article
- Blood cancer prediction using leukemia microarray gene data and hybrid logistic vector trees model.Scientific reports · 2022Article
- A Dual Level Analysis with Evolutionary Computing and Swarm Models for Classification of Leukemia.BioMed research international · 2022Article
- Non-small-cell lung cancer classification via RNA-Seq and histology imaging probability fusion.BMC bioinformatics · 2021Article
- A stacking ensemble deep learning approach to cancer type classification based on TCGA data.Scientific reports · 2021Article
- How artificial intelligence might disrupt diagnostics in hematology in the near future.Oncogene · 2021Review
- Advances in Electrochemical and Acoustic Aptamer-Based Biosensors and Immunosensors in Diagnostics of Leukemia.Biosensors · 2021Review
- Robust proportional overlapping analysis for feature selection in binary classification within functional genomic experiments.PeerJ. Computer science · 2021Article
- The use of data science to analyse physiology of oxygen delivery in the extracorporeal circulation.BMC cardiovascular disorders · 2019Observational
- Feature selection with the Fisher score followed by the Maximal Clique Centrality algorithm can accurately identify the hub genes of hepatocellular carcinoma.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In more recent years, a significant increase in the number of available biological experiments has taken place due to the widespread use of massive sequencing data. Furthermore, the continuous developments in the machine learning and in the high performance computing areas, are allowing a faster and more efficient analysis and processing of this type of data. However, biological information about a certain disease is normally widespread due to the use of different sequencing technologies and different manufacturers, in different experiments along the years around the world. Thus, nowadays it is of paramount importance to attain a correct integration of biologically-related data in order to achieve genuine benefits from them. For this purpose, this work presents an integration of multiple Microarray and RNA-seq platforms, which has led to the design of a multiclass study by collecting samples from the main four types of leukemia, quantified at gene expression. Subsequently, in order to find a set of differentially expressed genes with the highest discernment capability among different types of leukemia, an innovative parameter referred to as coverage is presented here. This parameter allows assessing the number of different pathologies that a certain gen is able to discern. It has been evaluated together with other widely known parameters under assessment of an ANOVA statistical test which corroborated its filtering power when the identified genes are subjected to a machine learning process at multiclass level. The optimal tuning of gene extraction evaluated parameters by means of this statistical test led to the selection of 42 highly relevant expressed genes. By the use of minimum-Redundancy Maximum-Relevance (mRMR) feature selection algorithm, these genes were reordered and assessed under the operation of four different classification techniques. Outstanding results were achieved by taking exclusively the first ten genes of the ranking into consideration. Finally, specific literature was consulted on this last subset of genes, revealing the occurrence of practically all of them with biological processes related to leukemia. At sight of these results, this study underlines the relevance of considering a new parameter which facilitates the identification of highly valid expressed genes for simultaneously discerning multiple types of leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.